Chimerix Inc - Utang jangka cendhak perusahaan CMRX

The market dynamics of Chimerix, Inc. (CMRX) demonstrate a current indicator of 0.00. The company's business relies on the development of cancer drugs. Geopolitical tensions are increasing demand for smallpox treatments, although sanctions complicate component logistics. Stock resilience depends on regulatory verdicts and research outcomes. Stability is ensured by a sufficient cash reserve to support drug trials for bone marrow transplantation.

CMRX (Chimerix) riwayat Utang jangka cendhak perusahaan saka 04.07.2022 nganti 26.04.2025

Chimerix Inc - rincian analitis lan metrik utama (CMRX)

- rega lan prakiraan konsensus rega:

Rega saham Chimerix|CMRX - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar Chimerix, Inc.|CMRX - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Nilai Buku saben Saham Chimerix|CMRX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku chimerix.com|CMRX - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Chimerix, Inc.|CMRX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Chimerix, Inc.|CMRX - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Chimerix, Inc.|CMRX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Chimerix

Pambiji fundamental perusahaan:Chimerix, Inc.

For the biopharmaceutical business of Chimerix, Inc. (CMRX), which holds government contracts for antiviral agents, managing liabilities with a maturity of up to one year is critical for assessing the stability of the operating cycle. By analyzing short-term financial debt, an investor can see the aggregate of creditor claims due within 12 months, which, combined with revenues from US government stockpiles, allows for the determination of the issuer's actual solvency and liquidity management efficiency.

Pesaing Chimerix, Inc. (CMRX)